| Yin, Rutie |
NCT06333821: A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma |
|
|
| Not yet recruiting | 3 | 460 | NA | Nimotuzumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy, placebo for Nimotuzumab, placebo | Biotech Pharmaceutical Co., Ltd. | Cervical Cancer | 04/30 | 04/30 | | |
| Completed | 2 | 150 | US, RoW | Paclitaxel, Afuresertib, LAE002 | Laekna Limited | Platinum-resistant Ovarian Cancer | 07/23 | 06/24 | | |
NCT05138887: A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis |
|
|
| Recruiting | 2 | 366 | RoW | Tetrahydrobiopterin | West China Second University Hospital | Radiation Enteritis | 10/23 | 03/24 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT06251388: A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer |
|
|
| Recruiting | 2 | 50 | RoW | AK104, Cadonilimab Injection | West China Second University Hospital, Affiliated Hospital of North Sichuan Medical College, The Affiliated Hospital Of Southwest Medical University | Cervical Cancer | 05/25 | 10/26 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
NCT05383482: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 |
|
|
| Active, not recruiting | 1/2 | 22 | RoW | Afuresertib, LAE002, Nab paclitaxel, Docetaxel, Sintilimab | Laekna Limited | Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma | 06/24 | 12/25 | | |
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 350 | US, RoW | IMP7068 | Impact Therapeutics, Inc., Covance | Advanced Solid Tumors | 04/23 | 08/23 | | |
NCT05270720: Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer |
|
|
| Not yet recruiting | 1 | 9 | RoW | dendritic cell | West China Second University Hospital | Recurrent Ovarian Cancer | 09/23 | 03/24 | | |
NCT05866354: To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies |
|
|
| Completed | 1 | 19 | RoW | Tisotumab Vedotin | Zai Lab (Shanghai) Co., Ltd. | Solid Malignancies | 11/23 | 11/23 | | |
| Not yet recruiting | 1 | 17 | RoW | KH801 | Beijing Kanghong Biopharmaceutical Co., Ltd. | Advanced Solid Tumors | 05/26 | 05/30 | | |
NCT06182917: Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients |
|
|
| Recruiting | N/A | 35 | RoW | | West China Second University Hospital | Ovarian Cancer | 12/25 | 06/26 | | |
| Zou, Qin |
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 350 | US, RoW | IMP7068 | Impact Therapeutics, Inc., Covance | Advanced Solid Tumors | 04/23 | 08/23 | | |
